Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Secondary osteoporosis and metabolic bone disease in patients 50 years and older with osteoporosis or with a recent clinical fracture: a clinical perspective

Bours, Sandrine P.G.a,b; van den Bergh, Joop P.W.b,c,d; van Geel, Tineke A.C.M.e; Geusens, Piet P.M.M.b,d


There were errors in table 3 of the recent article by Bours et al. , [1] . Citations were incorrectly added to the data in the prevalence columns during the typesetting process.

The publisher apologises for these errors and the correct table can be found below.

Current Opinion in Rheumatology. 26(5):604, September 2014.

Current Opinion in Rheumatology: July 2014 - Volume 26 - Issue 4 - p 430–439
doi: 10.1097/BOR.0000000000000074
METABOLIC BONE DISEASE: Edited by Kenneth G. Saag

Purpose of review The purpose of this review is to provide guidance to clinicians about which laboratory tests should be performed in patients with osteoporosis or with a recent fracture.

Recent findings Newly diagnosed secondary osteoporosis and other metabolic bone diseases (SECOB) have been found in 5–48% of patients with osteoporosis. In patients with a recent fracture, new SECOB is found in 10–47% of patients with osteoporosis, and in 26–51% if all patients with a fracture regardless of bone mineral density (BMD) are screened. More than one SECOB can be found in the same patient, even when they have already known SECOB. In primary hyperparathyroidism, hyperthyroidism, hypercortisolism, and multiple myeloma, both SECOB and its treatment have an impact on BMD and fractures. For other SECOBs, no treatment is available, or there are no data about the effect of treatment of the SECOB on BMD and fractures.

Summary We recommend performing the following tests in all patients with osteoporosis or a recent clinical fracture: calcium, phosphate, creatinine, albumin, erythrocyte sedimentation rate in all patients, 24 h urine calcium in men and serum testosterone in men less than 70 years. On indication, additional tests can be performed.

aDepartment of Rheumatology, Atrium Medical Centre, Heerlen

bDepartment of Internal Medicine, Subdivision of Rheumatology, Maastricht University Medical Centre, Maastricht

cDepartment of Internal Medicine, VieCuri Medical Centre, Venlo, The Netherlands

dUniversity of Hasselt, Hasselt, Belgium

eDepartment of General Practice, Maastricht University, Maastricht, The Netherlands

Correspondence to Piet P.M.M. Geusens, Department of Internal Medicine, Subdivision of Rheumatology, Maastricht University Medical Centre, PO Box 5800, 6202 AZ Maastricht, The Netherlands. Tel: +31 433877077; e-mail:

© 2014 Lippincott Williams & Wilkins, Inc.